At Last: Insulin Delivery Devices for the Bulk of the Diabetes Population
This article was originally published in Start Up
Executive Summary
In the field of insulin delivery devices, there have been three financings in as many months, including that of Calibra Medical, Cequr and Tandem Diabetes. The push into insulin delivery speaks to a broader trend in device investing. Investors and entrepreneurs are focusing more and more on bridging the gap between existing high-end devices that treat only a small subset of patients and basic, low-cost, almost commoditized products aimed at larger patient populations. In diabetes both of these drivers are in full force. In fact, perhaps to an even greater extent than other diseases, diabetes lends itself to a consumer mentality because patients with diabetes have to take several steps every single day to manage their own care.